Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13975733 | 0.87 | KCNH2 (0.86) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL13975812 | 0.86 | KCNH2 (1.00) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL13975551 | 0.81 | KCNH2 (0.75) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL19723036 | 0.80 | KCNH2 (0.88) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL15502397 | 0.80 | KCNH2 (0.88) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL13975735 | 0.79 | KCNH2 (0.86) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL15502399 | 0.78 | KCNH2 (1.00) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL13975895 | 0.77 | KCNH2 (0.64) | KCNH2TLR8TLR7 | |
| SCHEMBL14377304 | 0.75 | TLR7 (0.44) | KCNH2TLR8TLR7 | |
| SCHEMBL13975903 | 0.73 | KCNH2 (0.85) | KCNH2TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012156498-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN R&D IRELAND (IE) | 2012-11-22 | — | — | WO | disclosed |